Evidence map›Paper›PMID 40190351›Full record

ArticleBrain communications2025

Enduring differential patterns of neuronal loss and myelination along 6-month pulsatile gonadotropin-releasing hormone therapy in individuals with Down syndrome.

Michela Adamo, Mihaly Gayer, An Jacobs, Quentin Raynaud, Raphael Sebbah, Giulia di Domenicantonio, Adeliya Latypova, Nathalie Vionnet, Ferath Kherif, Antoine Lutti and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michela AdamoDepartment of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-9994-0945
Mihaly GayerLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
An JacobsDepartment of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Quentin RaynaudLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Raphael SebbahDepartment of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Giulia di DomenicantonioLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Adeliya LatypovaLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Nathalie VionnetDepartment of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-5420-8216
Ferath KherifLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Antoine LuttiLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Nelly PitteloudDepartment of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Bogdan DraganskiLaboratory for Research in Neuroimaging LREN, Centre for Research in Neurosciences, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.ORCID https://orcid.org/0000-0002-5159-5919

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite major progress in understanding the impact of the triplicated chromosome 21 on the brain and behaviour in Down syndrome, our knowledge of the underlying neurobiology in humans is still limited. We sought to address some of the pertinent questions about the drivers of brain structure differences and their associations with cognitive function in Down syndrome. To this aim, in a pilot magnetic resonance imaging (MRI) study, we monitored brain anatomy in individuals with Down syndrome receiving pulsatile gonadotropin-releasing hormone (GnRH) therapy over 6 months in comparison with typically developed age- and sex-matched healthy controls. We analysed cross-sectional (Down syndrome/healthy controls

Indexed as

brain tissue propertiesmagnetic resonance imagingmorphometrymulti-parameter mappingtrisomy 21

Identifiers

PMID40190351
PMCPMC11969670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.